PLK1活动的结构调节:对细胞循环功能和药物发现的影响
Danda Chapagai1, Klaus Strebhardt2, Michael D Wyatt3
1Krantz Family Center for Cancer Research, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, 02129, USA.
Cancer gene therapy
|May 16, 2025
概括
波罗样激酶1 (PLK1) 调节涉及复杂的结构变化和相互作用,对于细胞循环控制和癌症药物发现至关重要. 了解这些机制为抗癌提供了新的治疗策略.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 波罗样类激酶1 (PLK1) 是线粒分裂的关键调节剂,在癌症中经常过度表达,使其成为瘤学关键药物标.
- PLK1有一个激酶域 (KD) 和一个独特的C终端波罗盒域 (PBD),参与基质识别,定位和自抑制.
- PLK1调节受到翻译后修改,基结合,T210酸化,波拉蛋白相互作用以及单体和二元形式之间的转变的影响.
研究的目的:
- 审查最近对PLK1抑制的结构和机制见解.
- 阐明PLK1激活和调节的时间和空间要求.
- 讨论PLK1构造调节对细胞循环功能和癌症药物发现的影响.
主要方法:
- 关于PLK1结构,功能和调节的最新研究的文献综述.
- 对PLK1.1.中的翻译后修改和域-域相互作用的研究分析.
- 检查研究PLK1寡合化及其在细胞循环控制中的作用的研究.
主要成果:
- PLK1激活涉及过渡到一个开放的构造,克服通过T210酸化和相互作用等事件的自身抑制.
- PLK1存在于动态单体和二元形式,影响其在细胞周期中的活性和调节.
- 结构和机制的洞察力揭示了管理PLK1活动和本地化的复杂的监管网络.
结论:
- 了解PLK1的结构动态和调节机制对于开发有效的癌症疗法至关重要.
- 针对PLK1的调节途径为新型瘤药物开发提供了重大潜力.
- 复杂的PLK1调控突显了它在细胞周期进展和癌症发病过程中的核心作用.
相关概念视频
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...